The ibrutinib-venetoclax combination was particularly effective in patients with chronic lymphocytic leukemia with high-risk features such as IGHV unmutated disease or chromosomal abnormalities.
FDA approval of Bristol Myers Squibb’s Augtyro covers treatment of patients whose non-small cell lung cancer is driven by the rare ROS1 mutation. The molecule comes from BMS’s 2022 acquisition of Turning Point Therapeutics.
Women with breast cancer who had breast reconstruction following mastectomy did as well or better from shorter bursts of higher-dose radiation compared with conventional therapy, new data reveal.
Scientists have achieved a significant milestone in the fight against lung cancer by successfully navigating a steerable lung robot through living lung tissue. Lung cancer remains the leading cause of cancer-related deaths in the United States, with some tumors deeply hidden within lung tissue, posing a formidable challenge for surgeons.